Clinical Trial Update: Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Nous-209 genetic vaccine trial for microsatellite instability-high solid tumors is in Phase 1/Phase 2 and not currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Microsatellite Instability-high Solid Tumors
• Solid Tumors

Drugs mentioned

• Nous-209

Snippet

Sponsor: Nouscom SRL | Conditions: Solid Tumor, Adult | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING